Breo Ellipta’s Adolescent Data Could Be Highest Hurdle For Asthma Claim
This article was originally published in The Pink Sheet Daily
FDA’s Pulmonary-Allergy Drugs and Drug Safety and Risk Management advisors will cast separate votes March 19 on GSK’s ICS/LABA combo for patients 12-17 and for adults 18 and older.
You may also be interested in...
LABA prescribing patterns haven’t changed despite FDA’s labeling instructions on asthma safety concerns, agency concludes.
LABA safety issues may come to haunt GlaxoSmithKline as FDA’s Pulmonary-Allergy Drugs and Drug Safety and Risk Management advisory committees will focus on the combination’s product’s safety database and whether an outcomes study is needed for approval in asthma.
Follow-on may continue to face adoption challenges with expanded indication despite dosing convenience.